Palatin Technologies, Inc. Common Stock

Palatin Technologies, Inc. is a biopharmaceutical company that develops first-in-class medicines based on molecules that modulate the melanocortin receptor system. Its pipeline includes oral small molecule PL7737 MC4R agonist in preclinical studies, long-acting peptide MC4R agonists, and Bremelanotide co-administered with Tirzepatide for obesity in a Phase 2 trial. It also develops Bremelanotide co-formulated with a PDE5i for erectile dysfunction in patients not adequately responsive to PDE5i monotherapy, PL9643 for dry eye disease and anti-inflammatory ocular indications, and oral PL8177 for inflammatory bowel diseases. Incorporated in 1986, the company is based in Monmouth Junction, New Jersey.